Medicare Prescription Plans Limit Access to Recommended Drugs for Clostridioides difficile Infection.
Clostridioides difficile
Medicare
fidaxomicin
formulary
vancomycin
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
06 07 2022
06 07 2022
Historique:
received:
30
08
2021
pubmed:
10
10
2021
medline:
9
7
2022
entrez:
9
10
2021
Statut:
ppublish
Résumé
We analyzed June 2021 Medicare Advantage/Part D enrollment and formulary data. Oral vancomycin and fidaxomicin, frontline Clostridioides difficile treatments, were in the formulary for 100% (42314676 of 42314676) and 84.1% (35598385 of 42314676) of enrollees, respectively. However, they were broadly accessible (formulary, unrestricted, tier 1 or 2) to only 14.4% (6104348 of 42314676) and 1.1% (483004 of 42314676), respectively.
Identifiants
pubmed: 34626478
pii: 6385882
doi: 10.1093/cid/ciab898
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2227-2229Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.